RU2012120691A - Новый режим дозирования и способ лечения - Google Patents

Новый режим дозирования и способ лечения Download PDF

Info

Publication number
RU2012120691A
RU2012120691A RU2012120691/15A RU2012120691A RU2012120691A RU 2012120691 A RU2012120691 A RU 2012120691A RU 2012120691/15 A RU2012120691/15 A RU 2012120691/15A RU 2012120691 A RU2012120691 A RU 2012120691A RU 2012120691 A RU2012120691 A RU 2012120691A
Authority
RU
Russia
Prior art keywords
day
weeks
dosage regimen
administered
cancer
Prior art date
Application number
RU2012120691/15A
Other languages
English (en)
Russian (ru)
Inventor
Джон ЛАМБЕРТ
Джеймс Дж. О'ЛИРИ
Джоанн Элизабет Сара ШИНДЛЕР
Стивен УИТМАН
Альберт КИН
Original Assignee
Иммьюноджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммьюноджен, Инк. filed Critical Иммьюноджен, Инк.
Publication of RU2012120691A publication Critical patent/RU2012120691A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2012120691/15A 2009-10-21 2010-10-21 Новый режим дозирования и способ лечения RU2012120691A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
US61/253,804 2009-10-21
PCT/US2010/053579 WO2011050180A1 (en) 2009-10-21 2010-10-21 Novel dosing regimen and method of treatment

Publications (1)

Publication Number Publication Date
RU2012120691A true RU2012120691A (ru) 2013-11-27

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012120691/15A RU2012120691A (ru) 2009-10-21 2010-10-21 Новый режим дозирования и способ лечения

Country Status (13)

Country Link
US (1) US20110097345A1 (enExample)
EP (1) EP2490715A4 (enExample)
JP (1) JP2013508400A (enExample)
KR (1) KR20120094472A (enExample)
CN (1) CN102630165A (enExample)
AU (1) AU2010310577A1 (enExample)
BR (1) BR112012009250A2 (enExample)
CA (1) CA2775806A1 (enExample)
IL (1) IL219279A0 (enExample)
IN (1) IN2012DN02826A (enExample)
MX (1) MX2012004406A (enExample)
RU (1) RU2012120691A (enExample)
WO (1) WO2011050180A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2012008383A (es) * 2010-01-21 2012-11-23 Immunogen Inc Composiciones y metodos para el tratamiento de cancer de ovario.
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP2997044A4 (en) * 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
JP6463744B2 (ja) * 2013-10-08 2019-02-06 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CN109803660A (zh) * 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MX2020013466A (es) * 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US20230322933A1 (en) * 2020-06-04 2023-10-12 Bioinvent International Ab Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
WO2026117599A2 (en) * 2024-11-26 2026-06-04 Immunome, Inc. Immunoconjugates for ncam1 and methods of use
CN120053673B (zh) * 2025-02-11 2026-05-05 暨南大学 纳米前药及其制备方法和用途
CN120173115A (zh) * 2025-05-20 2025-06-20 苏州欣协生物科技有限公司 一种抗人cd56蛋白工程抗体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4776843B2 (ja) * 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
KR20060080535A (ko) * 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
EP1628631A2 (en) * 2003-06-05 2006-03-01 Achkar, Charles C. Methods of treating hyperproliferative cell disorders
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
KR20110028450A (ko) * 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
MX2012008383A (es) * 2010-01-21 2012-11-23 Immunogen Inc Composiciones y metodos para el tratamiento de cancer de ovario.
AU2012240448A1 (en) * 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer

Also Published As

Publication number Publication date
CN102630165A (zh) 2012-08-08
CA2775806A1 (en) 2011-04-28
IN2012DN02826A (enExample) 2015-07-24
US20110097345A1 (en) 2011-04-28
BR112012009250A2 (pt) 2017-06-20
WO2011050180A1 (en) 2011-04-28
MX2012004406A (es) 2012-05-08
EP2490715A4 (en) 2013-06-26
KR20120094472A (ko) 2012-08-24
EP2490715A1 (en) 2012-08-29
JP2013508400A (ja) 2013-03-07
IL219279A0 (en) 2012-06-28
AU2010310577A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
Foerster et al. Emerging immunotherapy for HCC: A guide for hepatologists
Dragu et al. Therapies targeting cancer stem cells: Current trends and future challenges
JP2013508400A5 (enExample)
US20220323475A1 (en) Combination therapy for cancer
Li et al. Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells
JP6053279B2 (ja) 癌を治療するための方法及び組成物
KR102566461B1 (ko) 조합 요법
US20230149436A1 (en) Combination therapy
MX2013012975A (es) Composiciones farmaceuticas.
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
Misir et al. circRNAs in drug resistance of breast cancer
US20030092638A1 (en) Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
AU2015278899A1 (en) Gemcitabine prodrugs
IL272095B (en) Cortaxolone 17alpha-valerate for use in the treatment of diseases associated with epithelial tumors
JP2017516802A5 (enExample)
CN107773556B (zh) 一种具有抗肿瘤药物功效的联合用药物
CN116490165A (zh) 阿比特龙前药
US12521425B2 (en) Method of liver cancer treatment with safranal-based formulations
Seo et al. Dexamethasone Mechanism in Inflammatory Immune Mediated Disease and its application in treating 2019 Coronavirus disease (COVID-19)
Brown et al. Topical tacrolimus with custom trays in the treatment of severe oral chronic graft-versus-host disease refractory to a potent topical steroid therapy: a case report
Schwarz et al. Medical Therapies of Cushing’s Disease–Part 1
US20200197430A1 (en) Combination Therapy
CN119136813A (zh) 阿比特龙前药
JP2020172471A (ja) ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物
CN105960236A (zh) 用于治疗间皮瘤的雌激素受体β激动剂